



ReShape Lifesciences Assembles World Class Scientific Advisory Board

June 6, 2018

SAN CLEMENTE, Calif., June 6, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ: [RSLS](#)), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the formation of the Company's Scientific Advisory Board (SAB), which includes the following five internationally recognized experts:

- Dr. Scott Shikora, Professor of Surgery Harvard Medical School & Director, Center for Metabolic and Bariatric Surgery Brigham and Women's Hospital, Boston, MA, ASMBS Past-President
- Dr. Jaime Ponce, Bariatric Surgeon, Medical Director of Bariatric Surgery CHI Memorial Hospital, Chattanooga, TN, ASMBS Past-President
- Dr. Philip Schauer, Professor of Surgery at the Cleveland Clinic Lerner College of Medicine, and Director of the Cleveland Clinic Bariatric and Metabolic Institute, ASMBS Past-President
- Dr. Natan Zundel, Professor of Surgery, Vice-Chairman Department of Surgery, Florida International University, Herbert Wertheim College of Medicine, IFSO Past-President
- Dr. John Morton, Chief of Bariatric and Minimally Invasive Surgery, Associate Professor of Surgery (General Surgery) at the Stanford University Medical Center, ASMBS Past-President

"We are pleased to welcome these world-renowned bariatric surgeons and leaders in weight loss and metabolic surgery to the ReShape Lifesciences™ team," said Dan Gladney, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences. "Creating the SAB represents another important step forward for the company. These advisors will work closely with our leadership team – providing their valuable experiences and insights - as we drive forward to be the leading provider of technologies to serve the continuum of care in obesity."

The SAB will provide scientific insight and advice as the Company expands the reach of its obesity technologies through both commercialization of its FDA-approved ReShape vBloc™ and ReShape Balloon™ products, as well as the development of additional products such as the ReShape Vest™

"There is an incredible unmet need for an effective and durable solution for millions of people struggling to lose weight, but for whom diet, exercise or drug therapy are not working," commented Dr. Schauer. "The ReShape Lifesciences minimally invasive technologies have strong potential to meet this unmet need in the near future."

About ReShape Lifesciences Inc.

ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved ReShape Balloon™ System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 kg/m² Body Mass Index (BMI) and at least one co-morbidity lose weight. ReShape vBloc™ Therapy, delivered by an FDA-approved pacemaker-like device called the ReShape vBloc System, is designed to help patients with a 40-45 kg/m², or a 35-39.9 kg/m² BMI and at least one co-morbidity feel full and eat less by intermittently blocking hunger signals on the vagus nerve. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this release include statements regarding our plans and objectives to be the leading provider of technologies to serve the continuum of care in obesity, our ability to expand the reach of our obesity technologies, and the potential of our technologies to meet the unmet need for an effective and durable solution for millions of people struggling to lose weight. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or

achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisitions of ReShape Medical, Inc. and BarioSurg, Inc.; risks related to the U.S. Food and Drug Administration's announcement to alert health care providers of unanticipated deaths involving the ReShape Balloon; our proposed ReShape Vest product may not be successfully developed and commercialized; our ability to continue as a going concern if we are unsuccessful in our pursuit of various funding options; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience; the competitive industry in which we operate; our ability to maintain compliance with the Nasdaq continued listing requirements; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our vBloc system or ReShape Balloon; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our annual report on Form 10-K filed April 2, 2018. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

SOURCE ReShape Lifesciences Inc.

Related Links

<http://www.reshapelifesciences.com>